Keyphrases
Acinar Cells
6%
Acute Cholangitis
10%
Acute Pancreatitis
42%
Autoimmune Pancreatitis
8%
Autophagy
8%
Betacellulin
8%
Boron Trichloride
7%
Cancer Patients
9%
Carbohydrate Antigen 19-9 (CA19-9)
9%
Cholangitis
6%
Chronic Pancreatitis
30%
Confidence Interval
13%
COVID-19 Pandemic
8%
Early Pancreatic Cancer
8%
Etiology
7%
Gemcitabine
18%
Gemcitabine Plus Nab-paclitaxel
10%
Induction Chemotherapy
8%
Inflammation
10%
Inflammatory Cytokines
7%
Interleukin-6
11%
Macrophages
7%
Metastasis
7%
Metastatic Pancreatic Cancer
13%
Mouse Model
10%
Nab-paclitaxel
8%
NF-B
25%
Nuclear factor-B
7%
Odds Ratio
11%
Olaparib
8%
Overall Survival
9%
Pancreas
30%
Pancreatic Cancer
76%
Pancreatic Carcinogenesis
8%
Pancreatic Ductal Adenocarcinoma
64%
Pancreatic Intraepithelial Neoplasia (PanIN)
10%
Pancreatic Tumor
7%
Pancreatitis
30%
Phase II Study
10%
Phase II Trial
8%
Placebo
6%
RelA
21%
Resectable Pancreatic Cancer
17%
Risk Factors
17%
Schwann Cells
8%
Severe Acute Pancreatitis
13%
Stent Therapy
7%
Therapeutic Potential
10%
Transcription Factor
7%
Tumor
13%
Medicine and Dentistry
Acute Hemorrhagic Pancreatitis
10%
Acute Pancreatitis
35%
Antibiotic Resistance
5%
Arm
5%
Autoimmune Pancreatitis
8%
Autophagy
11%
Cancer Cell
10%
Carcinogenesis
14%
Carisoprodol
16%
Chemotherapy
12%
Cholangitis
11%
Cholestasis
6%
Chronic Pancreatitis
22%
Clinical Trial
6%
COVID-19
8%
Cytokine
8%
Diagnosis
11%
Disease
20%
Endoscopic Retrograde Cholangiopancreatography
6%
Gemcitabine
17%
Germ Cell
8%
Induction Chemotherapy
8%
Interleukin 6
11%
Liver Metastasis
7%
Macrophage
7%
Malignant Neoplasm
26%
Metastatic Carcinoma
9%
Neoplasm
32%
Odds Ratio
11%
Olaparib
8%
Overall Survival
11%
Paclitaxel
9%
Pancreas Adenocarcinoma
57%
Pancreas Adenoma
7%
Pancreas Cancer
100%
Pancreas Tumor
7%
Pancreatic Duct
8%
Pancreatitis
25%
Pathogen
9%
Phase II Trials
8%
Placebo
9%
Protein P53
8%
Retrospective Study
9%
Schwann Cell
8%
Serositis
7%
Signal Transduction
5%
Surgery
8%
Survival Rate
5%
Tissue Injury
5%
Tumor Progression
9%
